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COST-EFFECTIVENESS ANALYSIS OF PIMOBENDAN COMPARED TO BENAZEPRIL FOR THE TREATMENT OF ACQUIRED MYXOMATOUS MITRAL VALVE DISEASE IN DOGS IN GERMANY
Poulsen Nautrup B p 1 , Poulsen Nautrup C 2 , Van Vlaenderen I 3 1 EAH Consulting, Juelich, Juelich, Northrhine Westf, Germany, 2 Ludwig-Maximilians University Munich, Munich, Bavaria, Germany, 3 Deloitte, Diegem, Diegem, Belgium OBJECTIVES: Myxomatous mitral valve disease (MMVD) presents a frequent heart problem in dogs. The inodilator pimobendan has shown to increase survival time of affected dogs when compared to the ACE inhibitor benazepril. The objective of this study was to estimate the cost-effectiveness of pimobendan compared to generic benazepril for treatment of MMVD in dogs in Germany. METHODS: A Markov model was developed to calculate costs and benefi ts of pimobendan and benazepril over a 1-year time horizon in dogs with MMVD on concurrent furosemide treatment. The model structure allowed for a differentiation in costs and transition probabilities between treatment start and maintenance treatment, and included the health states asymptomatic MMVD, symptomatic MMVD, treatment failure, euthanasia, and sudden death. Most transition probabilities were based on randomized controlled trials. Input-data on treatment pattern were derived from published literature, and cost data taken from offi cial price and tariff lists (year 2008, perspective of the dog owner). Missing data were obtained from experts in canine cardiology. RESULTS: Over the 1-year time horizon, mean total therapy cost per dog on pimobendan was €463.55 versus € 284.29 for benazepril. Mean survival was 274 days and 129 days for dogs on pimobendan and benazepril, respectively; resulting in a cost of € 1.24 for each additional day of life on pimobendan. Mean costs per treatment day were lower with pimobendan (€ 1.69) when compared to benazepril (€ 2.20). Extensive one-way and probabilistic sensitivity analyses confi rmed the robustness of the results. CON-CLUSIONS: Pimobendan is a cost-effective treatment of MMVD if the dog owner is willing to pay a price below the normal range of food costs in Germany for each additional day of life. Lower total treatment costs for benazepril are merely attributed to a shorter survival, as pimobendan resulted in less costs per treatment day compared to benazepril.
PHC4 COST-EFFECTIVENESS OF PIMOBENDAN VERSUS BENAZEPRIL IN ACQUIRED MYXOMATOUS MITRAL VALVE DISEASE IN DOGS: AN ADAPTATION TO SWITZERLAND
Poulsen Nautrup p B 1 , Van Vlaenderen I 2 1 EAH Consulting, Juelich, Juelich, Northrhine Westf, Germany, 2 Deloitte, Diegem, Diegem, Belgium OBJECTIVES: Myxomatous mitral valve disease (MMVD) presents a frequent heart problem in dogs. The objective of this study was to estimate the cost-effectiveness of pimobendan compared to benazepril for treatment of MMVD in dogs in Switzerland. METHODS: A Markov model including the health states asymptomatic MMVD, symptomatic MMVD, treatment failure, euthanasia, and sudden death, was adapted to Switzerland. Costs (year 2008, perspective of the dog owner) and benefi ts (life days gained, time without symptoms of heart failure) were calculated over a 1-year time horizon for dogs on pimobendan or benazepril respectively, both on concurrent furosemide treatment. Most transition probabilities were based on randomized controlled trials. Missing data and input-data on treatment pattern were obtained from experts in canine cardiology. RESULTS: Mean survival over the 1-year time horizon was 274 days for dogs on pimobendan versus 129 days for dogs on benazepril. Time spent without any symptoms of heart failure was 86 days for pimobendan versus 15 days for benazepril. Mean total therapy cost per dog on pimobendan was CHF 905.68 versus CHF 546.52 for benazepril; resulting in a cost of CHF 2.48 for each additional day of life on pimobendan. Mean costs per treatment day were lower with pimobendan (CHF 3.31) compared to benazepril (CHF 4.24) . Extensive one-way and probabilistic sensitivity analyses confi rmed the robustness of the results. CONCLUSIONS: Pimobendan is a cost-effective treatment of MMVD if the dog owner is willing to pay a price within the normal range of food costs for each additional day of life. The results indicate a better quality of life of dogs on pimobendan, as they spent substantially more time without any symptoms of heart failure compared to dogs on benazepril. Lower total treatment costs for benazepril are merely attributed to a shorter survival, as pimobendan resulted in less costs per treatment day.
PHC5 CHOICE OF HEMOSTATIC AGENT AND HOSPITAL LENGTH OF STAY IN CARDIOVASCULAR SURGERY
Krishnan S 1 , Conner TM 2 , Leslie RC 2 , Stemkowski S 3 1 Baxter BioSurgery, Westlake Village, CA, USA, 2 Outcomes Research Consulting, Austin, TX, USA, 3 Premier Inc, Charlotte, NC, USA OBJECTIVES: Hemostatic agents (HAs) are effi cacious in reducing blood loss during surgery, which may impact post-operative health care utilization and length of stay (LOS). The purpose of this study was to compare expected and actual LOS by choice of HA in cardiac procedures. METHODS: Hospital data were extracted from a large U.S. hospital-based, service-level comparative database. Procedures conducted between 2003 and 2006 were identifi ed using principal ICD-9 codes and limited by Diagnostic Related Groups (DRGs). Four cohorts for comparison were Floseal, Surgicel thrombin, Gelfoam thrombin, and other. Expected LOS was derived using 2006 Centers for Medicare and Medicaid (CMS) geometric mean LOS by DRG and two-part regression models were created to assess outcome. RESULTS: A total of 36,950 discharges were included. Floseal use was associated with signifi cantly less likelihood of exceeding the expected LOS compared to baseline (OR 0.791, p 0.01). Among patients who did exceed the expected LOS, Floseal patients did so at a reduced rate (IRR 0.891, p 0.01). Surgical use was not associated with any signifi cant difference from baseline, while Gelfoam use showed a slightly higher associated likelihood of exceeding expected LOS (OR 1.099, p 0.05). CONCLUSIONS: Floseal use was associated with lower than expected LOS in cardiac surgery. Given small profi t margins achieved by hospitals today, further assessment is warranted to distinguish products with favorable outcomes. An observational, longitudinal and prospective assessment, carried out in a pharmacy on subjects suffering from halitosis who were seeking an immediate remedy. The questionnaire used was the Halitosis Quality of Life Questionnaire (HQLQ), the only validated questionnaire regarding halitosis. RESULTS: A total of 311 subjects suffering from halitosis were included. The average age was 45.07 15.99 years. The sex ratio was 29.90% of men vs 70.10% of women. Also, 71.06% of the subjects exercised a professional activity. Seventy percent claimed they brushed their teeth after each meal; 44.23 of the subjects used accessories (26% inter-dental toothbrushes, 29% dental fl oss and 11% tongue scrapers). Sixty-six percent stated they became aware of halitosis themselves, 30% from a third party. Halitosis had been present for approximately 5 years; 11% had consulted only their halitosis. The overall HQ22 score was 14.68 7.86, after 7 days of treatment by Extract of green tea & Parsley essential oil, the score was 10.23 8.00. The improvement was statistically signifi cant (p 0.001). The evolution of each of the 4 dimensions ("daily life", "mental", "emotional", "social and work") also improved. The everyday life score changed from 2.95 2.10 to 1.89 1.92, the Emotional score changed from 2.46 2.10 to 1.81 1.95, the Mental score changed from 4.45 2.75 to 3.22 2.80 and the Social & Work dimension score changed from 4.92 2.50 to 3.54 2.60 CONCLUSIONS: Since using Extract of green tea & Parsley essential oil, 90% of subjects suffering from halitosis have experienced an improvement in their everyday lives, 83% feel more at ease in their cultural and social activities. These results confi rm the improvement of QoL among subjects suffering from halitosis after 7 days of treatment.
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PHC7 DEVELOPMENT AND VALIDATION OF SPECIFIC HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE FOR HALITOSIS: THE HALITOSIS QUALITY OF LIFE QUESTIONNAIRE (HQLQ)
Taieb C 1 , Maso H 2 1 Pierre Fabre, Boulogne, France, 2 PFOC, CASTRES, France OBJECTIVES: Halitosis or bad breath is a chronic condition affecting a large fraction of the adult population. The aim of this study was to develop and validate a halitosisspecifi c quality of life questionnaire for adults. METHODS: Development and validation of the questionnaire have been performed using the standardized multi-step method. RESULTS: A total of 169 eligible patients answered both questionnaires at day 0. Sixty-three did the same a second time at day 7. The initial pool of questions comprised 24 items. Two items were deleted, the fi rst was considered redundant and the due to ceiling effect, i.e., a ceiling effect means that most patients are not worried by a particular item. This resulted in a questionnaire of 22 items. Eleven items were allocated to each of the two domains. None of the items allocated to a domain showed a signifi cantly higher correlation with the total score of the other domain. CONCLU-SIONS: The fi nal version of the HQLQ contains 22 items covering 2 domains of quality of life assessment, namely "social and daily life activities" and "personal domain." The questionnaire is designed for self-administration. It showed both good reliability and construct validity. The intraclass correlation indicates good responsiveness of the HQLQ. To be valid, a questionnaire needs to be easily understood and completed by the population concerned. In summary, the health-related Quality of Life Questionnaire for halitosis is a valid instrument for use in adults complaining of bad breath. It is the fi rst ever to have been developed with this specifi c aim. Research suggests that regional variations in spending contribute to this crisis.
HEALTH CARE INTERVENTIONS -Health
Regional variations in the utilization of minimally invasive and conventional approaches to common surgeries is an extension of this paradigm, and likely contributes to disparities in health outcomes and expenditures across the nation. This study examines these factors through the lens of the following procedures: colectomy, laparoscopic and vaginal hysterectomy, esophagogastric fundoplasty, cholecystectomy, appendectomy, bariatric surgery, breast biopsy, ventral hernia repair, and lung reduction surgery. METHODS: We performed a retrospective cohort analysis using medical and pharmacy claims data from a large national health plan. Data on patient age, geographic residence, and severity were extracted. Geographic regions were categorized as West, Midwest, Northeast and South. Outcomes of interest included intraoperative and post-operative complications, length of hospital stay, infection rates and associated antibiotic utilization, and readmission rates. Total expenditures for health care utilization directly associated with a patient's surgery were estimated. Generalized linear models were constructed using a gamma distribution and log link function to estimate the effect of surgical approach on major outcomes while adjusting for other factors. RESULTS: Regional variations in utilization of laparoscopic and open surgeries are most pronounced for colectomy, hysterectomy, and bariatric surgery. Smaller but still signifi cant variations in the utilization of minimally invasive and conventional esophagogastric fundoplasty, appendectomy, and breast biopsy were also observed. Colectomy, vaginal hysterectomy, esophagogastric fundoplasty, cholecystectomy, appendectomy, breast biopsy, and lung reduction surgery were associated with lower follow-up health care expenditures when a minimally invasive route was used. CONCLUSIONS: Signifi cant regional variations in the utilization of minimally invasive and conventional approaches to common surgeries exist in the United States. To the extent that, surgical approach impacts infection risk, complications, length of stay, and other metrics, these variations contribute to disparities in health outcomes and expenditures.
